BioMedNewsBreaks

ThursdayMar 04, 2021 2:23 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leveraging AI, Proprietary Database to Improve Outcomes for Patients of Today and Tomorrow

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company focused on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, has been a forerunner in the field, helping oncologists individualize cancer treatment through its Helomics division. A recent article discussing this reads, “Predictive Oncology is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is…

Continue Reading

ThursdayMar 04, 2021 2:12 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Pipeline Holds Potential to Go Beyond Standard of Care for Anxiety, Depression

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications that go beyond the standard of care for anxiety and depression. A recent article discussing this reads, “Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these substantial issues. For example, FDA-approved oral antidepressants are slow to act and are associated with significant potential side effects such as anxiety, nausea and vomiting, somnolence and sexual dysfunction. VistaGen’s PH10 is an innovative pherine nasal spray designed to have rapid-onset therapeutic potential in several…

Continue Reading

ThursdayMar 04, 2021 1:12 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present at Upcoming H.C. Wainwright Global Life Sciences Conference

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the company’s CEO, John Climaco, will present at the virtual H.C. Wainwright Global Life Sciences Conference taking place March 9-10, 2021. According to the update, CNSP management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the event. Interested parties should visit https://ibn.fm/XlGLZ for more information and to register for the conference. To view the full press release,…

Continue Reading

ThursdayMar 04, 2021 11:29 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Unveils New Website, Completion of Corporate Rebranding Strategy

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, announced that it has completed its corporate rebranding efforts. Those efforts included the launch of a completely redesigned website. XPhyto chose to rebrand itself as part of its commitment to operational achievement in 2021, which included a number of product-development programs advancing from the laboratory to the clinic. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto is targeting focused investment in impact-driven innovation as well as value creation through commercialization of its development…

Continue Reading

WednesdayMar 03, 2021 2:32 pm

BioMedNewsBreaks – RYAH Group Inc. Set to be at Forefront of Data-Driven Medical Future

RYAH Group, a leading digital health care analytics and technology company, is set to benefit with a commitment to advancing the world’s transition to remote-health solutions and data analytics in patient treatments. A recent Becker’s Hospital Review article cites 10 emerging trends in health IT that will shape the field in 2021, reporting that big data management is increasingly necessary with the blossoming use of artificial intelligence (“AI”) and machine learning in health care (https://ibn.fm/ESnrL). RYAH is set to be at the forefront of the information-driven future as a company committed to leveraging the value of health devices combined with data…

Continue Reading

WednesdayMar 03, 2021 10:36 am

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Isolates and Concentrates a Mustard-Derived Molecule that Acts as a Systemic, Non-Selective Bioherbicide

MustGrow (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0), an agriculture biotech company focused on providing natural biological protection for high value crops, today announced that it has isolated and concentrated an additional molecule, thiocyanate, from mustard seed. According to the update, thiocyanate is responsible for the systemic activity behind the mustard plant's natural herbicidal (weed-killer) properties and is the third molecule from mustard seed that MustGrow has isolated, extracted and concentrated. MustGrow had previously announced herbicidal proof-of-concept success without isolating thiocyanate and now expects to build on those studies with identification of this additional herbicidal mode-of-action. MustGrow has commenced greenhouse testing…

Continue Reading

TuesdayMar 02, 2021 1:44 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes $10.2M Private Placement

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has closed its previously announced private placement to institutional and accredited investors. According to the update, the company sold 1,321,132 shares of its common stock at a purchase price of $7.75 per share for $10.2 million in the private placement. Processa Pharmaceuticals secured net proceeds of $9.9 million, which will enable the company to be funded through 2023 and either expand the clinical development of PCS6422 or conduct enabling toxicology studies to advance PCS11T. “We…

Continue Reading

TuesdayMar 02, 2021 1:00 pm

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Releases Results of New Clinical Study Showing Value of Personalization

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has announced the results of a new clinical study that examined the connection between personalization and sustained behavior change in digital health. The study indicates increased digital engagement resulted in 43% improvement in blood glucose levels. The study results were compiled in a paper titled "Role of Digital Engagement in Diabetes Care Beyond Measurement: Retrospective Cohort Study," which was published in the “Journal of Medical Internet Research (JMIR) Diabetes.” The study evaluated data from 998 people with Type 2 diabetes who used DarioHealth's digital health platform. The study focused…

Continue Reading

TuesdayMar 02, 2021 11:25 am

BioMedNewsBreaks – LexaGene Holdings Inc. (TSXV: LXG) (OTCQB: LXXGF) Secures $3.6M from Exercised Warrants

LexaGene Holdings (TSXV: LXG) (OTCQB: LXXGF), a molecular diagnostics company that develops fully automated rapid pathogen detection systems, today announced its receipt of approximately CA$3.6M (US$2.9M) in warrant exercises since the start of 2021. “Achieving our first commercial sales in combination with a very positive outlook for 2021 has resulted in the appreciation of our share price over the last few months,” said Dr. Jack Regan, LexaGene’s CEO and founder. “The receipt of exercised warrants has significantly added to our treasury and puts us in a strong financial position for 2021.” To view the full press release, visit https://ibn.fm/tqFbl About…

Continue Reading

TuesdayMar 02, 2021 10:47 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) to Participate in ‘Fireside Chat’ at Upcoming H.C. Wainwright Conference

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its chairman and CEO, James Sapirstein, will participate in a “fireside chat” with Yi Chen, managing director, Equity Research at H.C. Wainwright, during the H.C. Wainwright Global Life Sciences Conference being held virtually March 9-11, 2021. Sapirstein will provide an overview of AzurRx’ business and clinical development programs and discuss anticipated 2021 milestones during the fireside chat scheduled to take place at 7:00 a.m. ET on Tuesday, March 9. Additionally, Sapirstein and members of the AzurRx management team will be…

Continue Reading